Treatment Guidelines

American Urological Association (AUA)1

According to the AUA Guidelines for CRPC, apalutamide (ERLEADA®) with continued androgen deprivation is one of the options clinicians should offer to patients with non-metastatic CRPC at high risk for developing metastatic disease (Standard; Evidence Level Grade A).

AUA nomenclature*:

Standard: Directive statement that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be taken based on Grade A or B evidence.
Evidence Level Grade A: The quality of the evidence is high.

*The AUA rates the quality of evidence as high, moderate, or low (A, B, or C).

National Comprehensive Cancer Network® (NCCN®)2

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include apalutamide (ERLEADA®) with continued androgen deprivation as a Category 1 treatment option for patients with non-metastatic (M0) CRPC and a PSA doubling time ≤10 months.

Definition of non-metastatic (M0): Conventional imaging studies negative for distant metastases.

Category 1:

Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

CRPC = castration-resistant prostate cancer; PSA = prostate-specific antigen.

References

1. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. American Urological Association website: https://www.auanet.org/guidelines/castration-resistant-prostate-cancer (2013-amended-2018). Amended 2018. Accessed June 21, 2019.

2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed June 21, 2019. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.